Difference between revisions of "Team:Freiburg/Delivery"
D.Steinberg (Talk | contribs) |
|||
| Line 10: | Line 10: | ||
<div class="team_pic_div"> <img style="width:55%;float:left;margin-top:4%;" src="https://static.igem.org/mediawiki/2016/0/0e/T--Freiburg--DeliverySummary.png"> | <div class="team_pic_div"> <img style="width:55%;float:left;margin-top:4%;" src="https://static.igem.org/mediawiki/2016/0/0e/T--Freiburg--DeliverySummary.png"> | ||
<div style="width:55%;float:left;margin-top:3%;"> | <div style="width:55%;float:left;margin-top:3%;"> | ||
| − | <span style="font-size:14px"><b>Figure 1:</b> Depiction of GST displaying spores. Conversion process of CDNB and GSH to G-SDNB by GST displaying spores.</span> | + | <span style="font-size:14px"><b>Figure 1:</b> Depiction of GST displaying spores.<br> |
| + | Conversion process of CDNB and GSH to G-SDNB by GST displaying spores.</span> | ||
</div> | </div> | ||
<div style="margin-left:65%;margin-top:4%;"> | <div style="margin-left:65%;margin-top:4%;"> | ||
| Line 49: | Line 50: | ||
<center><img class="something" src="https://static.igem.org/mediawiki/2016/c/c0/T--Freiburg--ResultsDeliveryFigure2.png"> </center> | <center><img class="something" src="https://static.igem.org/mediawiki/2016/c/c0/T--Freiburg--ResultsDeliveryFigure2.png"> </center> | ||
| − | <b>Figure 2 | + | <b>Figure 2:</b> Scatter plot of immunostained spores displaying GST.<br> |
| + | Spores transformed with the part BBa_K2114011 driven by the promoter PCotYZ-RBS (BBa_K2114000) displayed GST and an HA epitope tag on their surface, which could be verified by staining with anti-HA antibodies conjugated to Alexa Fluor 647. The stained spores exhibited a higher fluorescence intensity. | ||
</font> | </font> | ||
| Line 71: | Line 73: | ||
<center><img class="something" src="https://static.igem.org/mediawiki/2016/e/e1/T--Freiburg--ResultsDeliveryFigure3.png"> </center> | <center><img class="something" src="https://static.igem.org/mediawiki/2016/e/e1/T--Freiburg--ResultsDeliveryFigure3.png"> </center> | ||
| − | <b>Figure 3 | + | <b>Figure 3:</b> GST assay with GST displaying spores compared to WT.<br> |
| + | <b>(A)</b> The GST assay was performed with 25 million GST-displaying spores (BBa_K2114001). The absorbance at 340 nm was monitored for a time course of 30 min. Unmodified wild type spores were used as reference (WT). <br> | ||
| + | <b>(B)</b> The increase of the absorbance in time is significantly higher for GST displaying spores compared to WT spores. | ||
</font> | </font> | ||
Revision as of 14:18, 19 October 2016
Results - Drug Delivery
Figure 1: Depiction of GST displaying spores.
Conversion process of CDNB and GSH to G-SDNB by GST displaying spores.
Conversion process of CDNB and GSH to G-SDNB by GST displaying spores.
Displaying a functional enzymatic moiety on the surface of the spores represents an essential feature for the activation of prodrugs. We evaluated glutathione-S-transferase (GST) displaying spores as potential carrier for the activation of azathioprine and verified their functionality in a colorimetric GST assay. The spores displaying GST exhibited an increased enzymatic activity in the conjugation of reduced glutathione (GSH) to 1-chloro-2,4-dinitrobenzene (CDNB) compared to unmodified spores and therefore provide evidence for their feasibility as a carrier for targeted drug delivery.
Introduction
The treatment of ulcerative colitis with the prodrug azathioprine and the conversion to its active form 6-mercaptopurine in the liver by glutathione S-transferase results in a systemic drug dispersion throughout the whole body, greatly harming healthy tissues as well as diseased cells. As a base analog 6-mercaptopurine inhibits the nucleic acid synthesis by inhibition of the purine metabolism, thus leading to apoptosis of highly proliferating cells. To ensure the local activation of the prodrug we modified the spores of B. subtilis to display a functional GST on their surface, which facilitates the activation of azathioprine. This approach provides that the enzymatic activity can be delivered to the affected sites in the gut and promotes the local treatment. Therefore, considerably lower amounts of the prodrug can be administered resulting in a reduction of systemic side effects. In order to confirm the feasibility of those modifications, analysis of the proper display of GST and its functionality is required.
Results
To determine the functionality of the displayed GST on the spores we first verified the localization on the surface of the spore. We assembled an integration vector containing a construct with GST fused to the spore coat gene cotG and a hemagglutinin epitope tag (BBa_K2114011), which was driven by the PCotYZ-RBS promoter (BBa_K2114000) and transformed them into B. subtilis. After selection the resulting spores should display GST on their surface. We verified the proper localization of the fusion protein by immunostaining with anti-HA antibodies conjugated to Alexa Fluor 647 and flow cytometry (Figure 2). Spores bound by the conjugated antibody appeared at a higher fluorescence intensity in the scatter plot. We observed two distinguishable populations, suggesting the presence of different stages in the spores.
Spores transformed with the part BBa_K2114011 driven by the promoter PCotYZ-RBS (BBa_K2114000) displayed GST and an HA epitope tag on their surface, which could be verified by staining with anti-HA antibodies conjugated to Alexa Fluor 647. The stained spores exhibited a higher fluorescence intensity.
To verify the functionality of the displayed GST we performed a colorimetric GST assay. This assay is based on the GST-catalyzed conjugation of the thiol group of reduced glutathione (GSH) to the GST substrate 1-chloro-2,4-dinitrobenzene (CDNB). The GST-catalyzed reaction produces a dinitrophenyl thioether which can be detected by a spectrophotometer at 340 nm. The modified spores displaying GST were incubated with the substrates and the absorbance was monitored for a time course of 30 min (figure 3 A). We could verify that spores displaying GST had a significantly increased change of absorbance at 340 nm in comparison to unmodified wild type spores (figure 3 B). We calculated the enzymatic activity from the linear increase of the absorbance at 340 nm and could determine a turnover of the substrate at 1.5 nmol/ml/min.
(A) The GST assay was performed with 25 million GST-displaying spores (BBa_K2114001). The absorbance at 340 nm was monitored for a time course of 30 min. Unmodified wild type spores were used as reference (WT).
(B) The increase of the absorbance in time is significantly higher for GST displaying spores compared to WT spores.
We could verify that GST is located on the surface of the spores and functional as shown by flow cytometry analysis and a GST assay.
During our experiments we observed that the spores unexpectedly exhibited two distinguishable populations in flow cytometry after staining with specific antibodies. We concluded that the spores most likely implicate distinct stages of sporulation, with different accessibility of the heterologous proteins that are displayed on the surface. Further optimization could increase the potential of Nanocillus. Such as the improvement of the display efficiency, through synchronization of the sporulation process, thus avoiding the heterogeneity of the spores. The simultaneous utilization of additional coat proteins besides CotG for the display of GST would result in a higher amount of displayed enzyme on the spore surface and thus an increased overall activity of the Nanocillus.
Nevertheless, due to their enormous versatility and modifiability we can conclude that our Nanocillus spores represent a promising approach for targeted drug delivery.
